This IDC Perspective provides IDC Health Insights' overview of key IT deals, news, and digital initiatives in the European life sciences and pharma industries in Q1 2021. In the evolving COVID-19 scenario, it is critical for European life sciences companies and their technology suppliers to closely follow the fast-moving trends and developments to promptly spot favorable opportunities and remain competitive during the crisis and beyond. This is the 11th in the quarterly series of reports IDC Health Insights has released as it continues to provide in-depth research coverage of diverse business and therapeutic areas in the European life sciences markets.
"The pandemic continues to drive major IT deals and initiatives in the European life sciences market. In the first quarter of 2021, the focus on digital solutions to enable decentralized and virtual trials and real-world data initiatives remained strong, not only to sustain R&D plans and accelerate time to market, but also to increase the global relevance of generated evidence. Investments are surging in digital solutions to support COVID-19 vaccines rollout. As the crisis pushes the expansion of healthcare and life sciences ecosystems, investments in digital technologies to support multi-stakeholder collaboration continue to grow." — Senior Research Analyst Nino Giguashvili, IDC Health Insights Europe